William A. Slusarchyk

An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits

John R. Wetterau, Richard E. Gregg, Thomas Harrity et al. · Science · 1998 · 268 citations

Hyperlipidemia, Whhl Rabbits, Metabolic Syndrome +17

Dual Metalloprotease Inhibitors:  Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase

Jeffrey A. Robl, Chong‐Qing Sun, Jay Stevenson et al. · Journal of Medicinal Chemistry · 1997 · 198 citations · Full text

Hypertension, Chemical Biology, Medicinal Chemistry +17

Discovery of (<i>R</i>)-7-Cyano-2,3,4,5-tetrahydro-1-(1<i>H</i>-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1<i>H</i>-1,4-benzodiazepine (BMS-214662), a Farnesyltransferase Inhibitor with Potent Preclinical Antitumor Activity

John T. Hunt, Charles Z. Ding, Roberta S. Batorsky et al. · Journal of Medicinal Chemistry · 2000 · 134 citations · Full text

Medicinal Chemistry, -1,4-Benzodiazepine Farnesyltransferase, Biochemistry +15

Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors

James Sutton, Scott A. Bolton, Karen S. Hartl et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 67 citations · Full text

Medicinal Chemistry, Medicine, Pharmacological Agent +5

Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors

James Sutton, Scott A. Bolton, Malcolm E. Davis et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 63 citations · Full text

Medicinal Chemistry, Solid-phase Synthesis, Medicine +5